Published in Law and Health Weekly, November 19th, 2005
For the 9 months ended September 30, 2005, VioQuest reported revenue of approximately $2.6 million, compared to revenue of $1.1 million for the 9 months ended September 30, 2004, or an increase of approximately 136%. During the third quarter, the company's subsidiary, Chiral Quest signed a license agreement with Merck & Co. to supply a variety of chiral catalysts and ligands.
As a pioneer in asymmetric synthesis, Chiral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly